Try our Advanced Search for more refined results

Watson To Pay $5.6B For Generic-Drug Maker Actavis

By Steven Melendez ( April 25, 2012, 7:37 PM EDT) -- New Jersey-based Watson Pharmaceuticals Inc. has agreed to buy Swiss drugmaker Actavis Group for €4. 25 billion (about $5. 6 billion) in a deal that would create the world's third-largest generic pharmaceuticals maker, with about $8 billion in revenue, the companies said Wednesday. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Law360 Reveals Titans Of The Plaintiffs Bar

This past year, a handful of attorneys secured billions of dollars in settlements and judgments for both classes and individual plaintiffs against massive companies and organizations like Facebook, Dell, the National Association of Realtors, Johnson & Johnson, UFC and Credit Suisse, earning them recognition as Law360's Titans of the Plaintiffs Bar for 2025.